TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05692960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnotic Relaxation Intervention (HRI)
Description: HRI is a combination intervention (Replens™ vaginal moisturizer device and hypnotic relaxation behavioral intervention)

Intervention type: DEVICE
Group type: OTHER
Intervention: Vulvovaginal Atrophy (VVA)
Description: VVA is a standard of care intervention (Replens™ vaginal moisturizer device)
Study: NCT05686551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tominersen 60 mg
Description: 60 mg tominersen administered intrathecally every 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered intrathecally every 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tominersen 100 mg
Description: 100 mg tominersen administered intrathecally every 16 weeks
Study: NCT06469788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video comprised of AIRD patient narratives on COVID-19 vaccination thoughts and experiences
Description: Participants will watch video focused on the importance of receipt of updated COVID-19 vaccination in patients with AIRD

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video on the importance of good oral health for patients with AIRD
Description: Participants will watch video on the importance of good oral health in AIRD patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brochure on COVID-19 vaccination in AIRD patients
Description: Participants

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Participants will receive phone calls from patient navigators to provide support and information for receipt of updated COVID-19 vaccination in patients with AIRD

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brochure on the importance of good oral health in AIRD patients
Description: Participants will receive a brochure on the importance of good oral health in AIRD patients.
Study: NCT05186753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezuclastinib Tablets (Formulation A)
Description: Bezuclastinib will be administered orally, once daily continuously for 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezuclastinib Tablets (Formulation A)
Description: Bezuclastinib will be administered orally, once daily continuously for 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezuclastinib Tablets (Formulation A)
Description: Bezuclastinib will be administered orally, once daily continuously for 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezuclastinib Tablets (Formulation B)
Description: Bezuclastinib will be administered orally, once daily continuously for 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezuclastinib Tablets (Formulation B)
Description: Bezuclastinib will be administered orally, once daily continuously for 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezuclastinib Tablets (Formulation B)
Description: Bezuclastinib will be administered orally, once daily continuously for 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezuclastinib Tablets (Formulation B)
Description: Bezuclastinib will be administered orally, once daily continuously for 28-day cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Placebo will be administered orally, once daily continuously for 28-day cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Placebo will be administered orally, once daily continuously for 28-day cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Placebo will be administered orally, once daily continuously for 28-day cycles
Study: NCT05139017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zilovertamab vedotin
Description: Intravenous (IV) Infusion 1.5 mg/kg, 1.75 mg/kg, 2.0 mg/kg, 2.25 mg/kg, 2.5 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zilovertamab vedotin
Description: Intravenous (IV) Infusion 1.5 mg/kg, 1.75 mg/kg, 2.0 mg/kg, 2.25 mg/kg, 2.5 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zilovertamab vedotin
Description: Intravenous (IV) Infusion 1.5 mg/kg, 1.75 mg/kg, 2.0 mg/kg, 2.25 mg/kg, 2.5 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zilovertamab vedotin
Description: Intravenous (IV) Infusion 1.5 mg/kg, 1.75 mg/kg, 2.0 mg/kg, 2.25 mg/kg, 2.5 mg/kg

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: IV Infusion 375 mg/m\^2

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: IV Infusion 375 mg/m\^2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV Infusion 375 mg/m\^2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV Infusion 375 mg/m\^2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV Infusion 375 mg/m\^2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV Infusion 375 mg/m\^2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV Infusion 1000 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV Infusion 1000 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV Infusion 1000 mg/m\^2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: IV Infusion 100 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV Infusion 100 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV Infusion 100 mg/m\^2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: IV Infusion 90 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: IV Infusion 90 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: IV Infusion 90 mg/m\^2
Study: NCT06208150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered as a SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered as a SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pomalidomide will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered as a SC injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elotuzumab
Description: Elotuzumab will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered either orally or intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered either orally or intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be administered either orally or intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib will be administered as a SC injection.
Study: NCT05386914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: 1 mg of Sirolimus taken orally once a day for 4 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Sirolimus
Description: 1 mg of Sirolimus taken orally once a day for 4 weeks.
Study: NCT04799015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10mg
Description: Metoclopramide 10mg IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoclopramide 10mg
Description: Metoclopramide 10mg IV
Study: NCT05901636

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INFLUENZA G1 mHA
Description: INFLUENZA G1 mHA will be administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INFLUENZA G1 mHA
Description: INFLUENZA G1 mHA will be administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INFLUENZA G1 mHA
Description: INFLUENZA G1 mHA will be administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INFLUENZA G1 mHA
Description: INFLUENZA G1 mHA will be administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INFLUENZA G1 mHA
Description: INFLUENZA G1 mHA will be administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INFLUENZA G1 mHA
Description: INFLUENZA G1 mHA will be administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Al(OH)3
Description: Al(OH)3 will be administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Al(OH)3
Description: Al(OH)3 will be administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Al(OH)3
Description: Al(OH)3 will be administered intramuscularly.
Study: NCT04829318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine will be self-administered as nasal spray.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI/SNRI
Description: Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the summary of product characteristics (SmPC) (or local equivalent, if applicable). During this LTE study, investigators will be allowed to switch individual participant's SSRI/SNRI for tolerability issues.
Study: NCT06121050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pet visit
Description: Intensive care patients visited by their pets for 20 minutes
Study: NCT04593732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STERN FIX (Sternal Stabilization System)
Description: Sternotomy closure with STERN FIX and supplemented with wires
Study: NCT04610294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functioning Aerus air filtration/sterilization
Description: Two units of Aerus air sterilization system will be used in each operating room, and each will be set to high. Units used for the trial will be modified internally to be active and will be sealed to prevent operating room personnel from opening the system and determining a unit's status.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deactivated Aerus air filtration/sterilization
Description: Two units of Aerus air sterilization system will be used in each operating room, and each will be set to high. Units used for the trial will be modified internally to be inactivated and will be sealed to prevent operating room personnel from opening the system and determining a unit's status. Units will be inactivated by removing the activated carbon, high-efficiency particulate filter, and ionization chamber. However, the fan will remain active as will the run lights.
Study: NCT06315231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone dexborneol sublingual tablet
Description: Patients will receive one edaravone dexborneol sublingual tablet twice daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive one placebo twice daily for 24 weeks
Study: NCT05624125

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: Two 70 ml beetroot juice drinks daily for 4 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two 70 ml placebo drinks daily for 4 months.
Study: NCT04630028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab Dose Based on BSA and Body Weight
Description: As per BSA and body weight Ustekinumab will be administered SC and IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab Dose Based on BSA and Body Weight
Description: As per BSA and body weight Ustekinumab will be administered SC and IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab Dose Based on BSA and Body Weight
Description: As per BSA and body weight Ustekinumab will be administered SC and IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Placebo will be administered subcutaneously.
Study: NCT04630145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Participants will receive BDQ tablets only/

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Participants will receive CAM 400 or 500 mg twice a day.
Study: NCT04858490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Symptom-triggered diazepam treatment: 10 or 20mg, at the clinician's discretion
Study: NCT04630145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Participants will receive CAM 400 or 500 mg twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Participants will receive 500 to 750 mg daily (maximum daily dose of 1.0 gram \[g\]) or 15 mg/kg once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Participants will receive 500 to 750 mg daily (maximum daily dose of 1.0 gram \[g\]) or 15 mg/kg once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Participants will receive daily dose is 450 mg (maximum 600 mg) RFP capsule once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifabutin
Description: Participants will receive daily dose of RBT 300 mg or 150 mg capsules once a day.
Study: NCT00927121

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset
Description: The CR-stimulation was originally developed by Prof. Dr. Dr. Peter Tass for deep brain stimulation (DBS). The CR-stimulation through high frequency short pulses causes a neuronal reorganization in the stimulated brain area establishing a normal neuronal activity.~Based on intensive modeling studies, experimental proof of concept (POC) animal studies and a clinical POC, we proved that the pathologic activity can be recuperated to a desynchronized/healthy state with the acoustic CR-stimulation.~The acoustic CR-stimulation signal will be generated by the ANM CR-Stimulator and transmitted to the ears through a speaker system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset
Description: The CR-stimulation was originally developed by Prof. Dr. Dr. Peter Tass for deep brain stimulation (DBS). The CR-stimulation through high frequency short pulses causes a neuronal reorganization in the stimulated brain area establishing a normal neuronal activity.~Based on intensive modeling studies, experimental proof of concept (POC) animal studies and a clinical POC, we proved that the pathologic activity can be recuperated to a desynchronized/healthy state with the acoustic CR-stimulation.~The acoustic CR-stimulation signal will be generated by the ANM CR-Stimulator and transmitted to the ears through a speaker system
Study: NCT05167825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan will be administered orally as a tablet.
Study: NCT05686070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asundexian (BAY2433334)
Description: Once daily, oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to asundexian, once daily, oral
Study: NCT04496895

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: consume 1 sachet per day for 2 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: orange peel fermentation
Description: consume 1 sachet per day for 2 months
Study: NCT05658224

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education on effects of Exercise-induced hypoalgesia from exercise
Description: Educational session with participants

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education on effects of Exercise-induced hypoalgesia from exercise
Description: Educational session with participants
Study: NCT06497465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50mg Tab
Description: Participants will receive Dolutegravir 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO]
Description: Participants will receive Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet \[DOVATO\]
Study: NCT00927121

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset
Description: The CR-stimulation was originally developed by Prof. Dr. Dr. Peter Tass for deep brain stimulation (DBS). The CR-stimulation through high frequency short pulses causes a neuronal reorganization in the stimulated brain area establishing a normal neuronal activity.~Based on intensive modeling studies, experimental proof of concept (POC) animal studies and a clinical POC, we proved that the pathologic activity can be recuperated to a desynchronized/healthy state with the acoustic CR-stimulation.~The acoustic CR-stimulation signal will be generated by the ANM CR-Stimulator and transmitted to the ears through a speaker system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset
Description: The CR-stimulation was originally developed by Prof. Dr. Dr. Peter Tass for deep brain stimulation (DBS). The CR-stimulation through high frequency short pulses causes a neuronal reorganization in the stimulated brain area establishing a normal neuronal activity.~Based on intensive modeling studies, experimental proof of concept (POC) animal studies and a clinical POC, we proved that the pathologic activity can be recuperated to a desynchronized/healthy state with the acoustic CR-stimulation.~The acoustic CR-stimulation signal will be generated by the ANM CR-Stimulator and transmitted to the ears through a speaker system

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset
Description: The CR-stimulation was originally developed by Prof. Dr. Dr. Peter Tass for deep brain stimulation (DBS). The CR-stimulation through high frequency short pulses causes a neuronal reorganization in the stimulated brain area establishing a normal neuronal activity.~Based on intensive modeling studies, experimental proof of concept (POC) animal studies and a clinical POC, we proved that the pathologic activity can be recuperated to a desynchronized/healthy state with the acoustic CR-stimulation.~The acoustic CR-stimulation signal will be generated by the ANM CR-Stimulator and transmitted to the ears through a speaker system
Study: NCT06497465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO]
Description: Participants will receive Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet \[DOVATO\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)
Description: Participants will receive Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)
Study: NCT04562441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib: 5 mg bd po Day 1 to Day 28
Study: NCT04778943

Intervention type: OTHER
Intervention: Surgery(OLIF and MIS-TLIF)
Description: oblique lateral interbody fusion (OLIF); minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF)

Intervention type: OTHER
Intervention: Surgery(OLIF and MIS-TLIF)
Description: oblique lateral interbody fusion (OLIF); minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF)
Study: NCT04562441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab: 10 mg/kg Day 1 to Day 15 every 4 weeks
Study: NCT04750798

Intervention type: DEVICE
Intervention: BWI Medical Device
Description: Participants will be treated with commercially approved BWI medical devices following routine clinical practice. No specific intervention will be observed for this study.

Intervention type: DEVICE
Intervention: Varipulse Catheter
Description: Participants treated with Varipulse Catheter in the main study will be part of the VARIPURE sub-study. No specific intervention will be observed for this study.
Study: NCT05306314

Intervention type: DIETARY_SUPPLEMENT
Intervention: TREATAPROST
Description: oral administration before meals 30 minutes

Intervention type: DIETARY_SUPPLEMENT
Intervention: TREATAPROST
Description: oral administration before meals 30 minutes
Study: NCT06094283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YCT-529
Description: Single oral dose (planned doses of 10, 30, 90 and 200 mg; dose levels will not exceed 250 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YCT-529 Placebo
Description: YCT-529 Placebo